My ePortfolio Register   

ASH 2016 /
TCA cycle inhibition by CPI-613 increases chemo sensitivity in older AML patients

3rd - 6th Dec 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.12.16
Views: 1828
Rating:

Dr Timothy Pardee - Wake Forest Baptist Medical Center, Winston-Salem, USA

Dr Pardee speaks with ecancertv at ASH 2016 about CPI-613, a novel agent which inhibits the citric acid cycle (TCA).

He describes how blocking metabolic pathways with CPI-613 starves leukaemia cells of energy and reduces treatment resistance, especially when combined with cytarabine (ara-c) for older patients with relapse acute myeloid leukaemia.

Dr Pardee summarises RNA-seq analysis of patient bone marrow as highlighting a possible gene signature of best responders.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence